Predictors and biomarkers of treatment gains in a clinical stroke trial targeting the lower extremity

https://escholarship.org/uc/item/7mt8d3m4

Stroke, 45(8)

0039-2499

Burke, E
Dobkin, BH
Noser, EA
et al.

2014

10.1161/STROKEAHA.114.005436

CC BY 4.0

Peer reviewed
Predictors and biomarkers of treatment gains in a clinical stroke trial targeting the lower extremity

Erin Burke, BS1, Bruce H. Dobkin, MD2, Elizabeth A. Noser, MD3, Lori A. Enney, BS4, and Steven C. Cramer, MD1,5

1Dept Anatomy & Neurobiology, University of California, Irvine
2Dept Neurology, University of California, Los Angeles
3Dept Neurology, University of Texas, Houston
4GlaxoSmithKline, Neurosciences Therapy Area Unit
5Dept Neurology, University of California, Irvine

Abstract

Background and Purpose—Behavioral measures are often used to distinguish subgroups of stroke patients, e.g., to predict treatment gains, stratify clinical trial enrollees, or select rehabilitation therapy. In studies of the upper extremity, measures of brain function using fMRI have also been found useful, but this approach has not been examined for the lower extremity. The current study hypothesized that an fMRI-based measure of cortical function would significantly improve prediction of treatment-induced lower extremity behavioral gains. Biomarkers of treatment gains were also explored.

Methods—Patients with hemiparesis 1-12 months post-stroke were enrolled in a double-blind, placebo-controlled, randomized clinical trial of ropinirole+physical therapy vs. placebo+physical therapy, results of which have previously been reported (NCT00221390). Primary endpoint was change in gait velocity. Enrollees underwent baseline multimodal assessment that included 19 measures spanning five assessment categories (medical history, impairment, disability, brain injury, and brain function), and also underwent reassessment three weeks after end of therapy.

Results—In bivariate analysis, eight baseline measures belonging to four categories (medical history, impairment, disability, and brain function) significantly predicted change in gait velocity. Prediction was strongest, however, using a multivariate model containing two measures (leg Fugl-Meyer score and fMRI activation volume within ipsilesional foot sensorimotor cortex). Increased activation volume within bilateral foot primary sensorimotor cortex correlated positively with treatment-induced leg motor gains.
Conclusions—A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting. Results also suggest potential utility of fMRI measures as biomarkers of treatment gains.

Keywords
stroke; neuroimaging; plasticity; predictor; biomarker; stratification

Introduction
Difficulty with lower extremity control is a major contributor to post-stroke disability, with one-third to two-thirds of survivors having gait difficulties\(^1,2\). A number of restorative therapies have the potential to improve behavioral outcomes after stroke\(^3\). However, the heterogeneous nature of stroke is an obstacle to effective clinical implementation. For example, differences in age, injury, and behavioral deficits can each increase inter-subject variability in treatment response.

Improved methods are needed to identify distinct patient subgroups, such as those who will respond to a post-stroke therapy from those who will not. Numerous measures have been used to predict post-stroke outcomes such as gait, particularly behavior and other clinical measures\(^4,5\). Studies of the upper extremity have emphasized the utility of a multimodal approach, whereby different forms of assessment, including measures of cortical function or neurophysiology, are combined to best predict treatment response\(^6,7\). To date, this approach has not been examined for the lower extremity. The main goal of the current study was to examine a multimodal set of measures, including measures of cortical function, in order to identify the best approach for predicting response to treatment targeting the lower extremity in the setting of chronic stroke. A better understanding of predictors could inform clinical trial design, for example, in relation to entry criteria or patient stratification\(^8\).

A secondary study goal was to explore potential biomarkers of treatment effect. The molecular and cellular events underlying treatment-induced behavioral gains are difficult to measure directly in humans, but methods such as fMRI can provide insights, albeit indirectly, into treatment effects\(^9\). A core feature of a valid biomarker is that it changes in parallel with treatment-induced behavioral gains. A number of studies have described changes in cortical activation that correlate with motor gains from therapies targeting upper extremity function\(^10-14\). Limited data exist, however, in relation to treatments targeting the lower extremity after stroke.

These issues were examined in the setting of a clinical trial (NCT00221390)\(^15\). Enrollees underwent multimodal evaluation at baseline that included 19 measures spanning five assessment categories (medical history, impairment, disability, brain injury, and brain function) and gait velocity was assessed to three weeks post-therapy. The primary hypothesis of the current study was that an fMRI-based measure of cortical function would be an independent, significant predictor of change in gait velocity across the period of therapy, as has been described in therapeutic studies targeting the upper extremity\(^6,7\).
Materials and Methods

Study overview and subjects

The clinical trial was a randomized, double-blind, placebo-controlled study that compared 9 weeks of ropinirole+physical therapy (PT) vs. placebo+PT in patients with chronic stroke. The primary endpoint was change in gait velocity from baseline to week-12, three weeks after end of therapy (Figure 1). Secondary endpoints included two measures of impairment related to the leg: change in leg Fugl-Meyer (FM) score and in gait endurance. Entry criteria included ischemic or hemorrhagic stroke 1-12 months prior, age 18-80, and motor deficits that were neither very mild (arm+leg FM motor score <84 out of 100) nor very severe (FM score >22). Exclusion criteria included gait difficulty that was either very mild (gait velocity >1 m/sec) or very severe (FIM ambulation score<3). Patients took escalating doses of ropinirole vs. placebo once daily for 9-weeks; starting week-5, each also received 90-minutes of standardized physical therapy (PT) twice/week. Full clinical trial details have been published15.

Assessments

A battery of behavioral assessments was performed at baseline (Table 1), some of which (gait velocity, leg FM scale, gait endurance, Hamilton Depression score, Barthel Index, and Stroke Impact Scale-16.) were repeated at the week-12 visit.

MRI data acquisition

Subjects without contraindication to MRI were scanned twice: (1) at baseline, before the first dose of drug, and (2) at the post-therapy visit that occurred in week-12. Subjects were positioned in the scanner (1.5 T), knees flexed atop a pillow, with bilateral MRI-compatible ankle splints that went from tibia-to-toes and restricted the ankle to 10° dorsiflexion/plantarflexion while preventing lateral leg rotation. Scanning included a T1-weighted anatomical scan plus fMRI scan during which subjects executed 0.25 Hz ankle dorsiflexion/plantarflexion. Further MRI acquisition details appear in Supplemental Methods.

Image processing and analysis

The fMRI images were analyzed using SPM2. For each subject, the first two volumes were removed because of tissue non-saturation. Remaining images were realigned, coregistered to the volumetric scan, spatially normalized, transformed into MNI stereotaxic space, and spatially smoothed (FWHM=8 mm). Images at rest were contrasted with images during attempted foot movement, using measures of head motion as covariates, in order to create a contrast image for each subject. Scans with excess head movement were discarded.

Two regions of interest were drawn in MNI stereotaxic space, representing the foot area of primary sensorimotor cortex in the right and left hemispheres (see Figure 1D of Cramer et al16). Two measures of brain function were extracted from each subject's fMRI activation map: activation volume, determined on each brain side at threshold Z=3 (approximately p < 0.001) uncorrected for multiple comparisons, and activation magnitude, determined on each brain side as the task-related signal change using MarsBaR. These calculations were performed twice for each subject (on the baseline and on the week-12 fMRI scan).
In addition to fMRI, imaging analyses also included two measures of brain injury: infarct volume and % injury to the corticospinal tract (CST). Infarct volume was calculated by outlining by hand each subject’s infarct on the T1-weighted MRI. Corticospinal tract injury was evaluated as the amount of overlap between each subject’s infarct with an M1 corticospinal tract in MNI stereotaxic space derived from diffusion tensor imaging tractography in healthy control subjects (Further MRI imaging analysis details appear in Supplemental Methods).

Statistics

Statistical analyses used JMP-8 software (SAS Institute, Cary, NC), were 2-tailed, and used alpha=0.05. Normally distributed data, and data that could be transformed to a normal distribution, were analyzed using parametric statistics, otherwise non-parametric statistics were used. The clinical trial found that the two treatment groups showed no significant differences in change for the primary or secondary behavioral endpoints or in the time X group interaction term\textsuperscript{15}, and so the two arms were combined for current analyses.

Primary analyses examined predictors of behavioral gains. The dependent variable was the clinical trial’s primary outcome measure, change in gait velocity. First, 19 baseline measures from five categories (medical history, impairment, disability, brain injury, and brain function) were screened as predictors in bivariate analyses. Next, those baseline measures with p<0.10 in bivariate analyses were advanced into a forward stepwise multivariate model (p<0.1 to enter, p<0.15 to leave). Due to high collinearity among baseline impairment measures, only the one showing the strongest correlation with change in gait velocity (leg FM) was entered into the model; the same was true for disability measures (where Barthel Index showed the strongest correlation and was entered into the model).

Secondary analyses assessed the performance of four fMRI-based measures as biomarkers of behavioral gains. These four were change in ipsilesional and contralesional activation volume, and change in ipsilesional and contralesional activation magnitude. Performance of each biomarker candidate was evaluated based on the strength of its correlation with behavioral change over the same period. Behavioral change was examined with each measure of leg impairment (gait velocity, gait endurance, and leg FM score) in this exploratory analysis, using alpha=0.0042 based on a Bonferroni correction for 12 comparisons.

Results

Subjects and clinical trial overview

A total of 33 subjects were enrolled (Table 1). All subjects had complete data except for MRI measures: MRI was not performed at U Texas (4 subjects) and could not be completed (e.g., due to claustrophobia) in 5 subjects at baseline and 7 at week-12. In addition, 4 baseline and 3 week-12 fMRI scans were excluded due to excess head movement. This left 24 anatomical MRI and 20 fMRI scans at baseline, plus 22 anatomical and 19 fMRI scans at week-12. During fMRI scanning, all subjects attempted movement as requested.
Enrollees on average were 7 months post-stroke, had moderate impairment, and moderate size infarcts. Ipsilesional activation was greater than contralesional activation within foot primary sensorimotor cortex, in both volume and magnitude. Gait velocity, and most of the secondary behavioral measures, showed significant improvement from baseline to week-12 (Table 1).

Predicting behavioral gains

In bivariate analyses, 8 of the 19 baseline measures were found to predict change in gait velocity from baseline to week-12 (Table 2). These predictors included assessments from four categories (medical history, impairment, disability, and brain function), but not from the fifth category (brain injury). Data for one of these measures, activation volume within ipsilesional foot primary sensorimotor cortex, are presented in Figure 2.

These predictors were entered into a forward stepwise multivariate model. The final model found that change in gait velocity was predicted (r²=0.63, p=0.0002) by two baseline measures: one based on behavior (leg FM score, p=0.002) and one based on brain function (fMRI activation volume within ipsilesional foot primary sensorimotor cortex, p=0.03).

Performance of fMRI measures as biomarkers of behavioral gains

The evolution of four fMRI measures from baseline to week-12 was evaluated in relation to behavioral gains over the same time interval. Although on average none of these fMRI changes was significant (Table 1), two correlated with change in behavior: change in ipsilesional activation volume correlated with change in leg FM score (p=0.04), and change in contralesional activation volume correlated with change in leg FM score (p=0.0043) as well as change in gait endurance (p=0.05). Each showed an increase in activation volume over time that correlated positively with extent of motor improvement, but did not survive formal Bonferroni correction (alpha=0.0042). Change in activation magnitude did not correlate with change in any behavioral measure. For no fMRI measure did change over time correlate with change in gait velocity.

Correlates of fMRI brain activation

To aid interpretation of these results, behavioral-fMRI correlations were examined at baseline and at week-12. At baseline, none of the three measures of leg impairment (gait velocity, gait endurance, leg FM score) correlated (p>0.05) with any fMRI measure. At week-12, however, all three behavioral measures showed a significant positive relationship with both ipsilesional and with contralesional activation volume. Specifically, week-12 gait velocity correlated with ipsilesional (rho=0.55, p=0.02) and contralesional (rho=0.63, p=0.004) activation volume, as did gait endurance (rho=0.48, p=0.04 and rho=0.59, p=0.01, respectively), and leg FM score (rho=0.66, p=0.002 and rho=0.46, p=0.046, respectively). No week-12 behavioral measure correlated with activation magnitude, on either brain side.

Discussion

There is wide variability in the degree of benefit that patients with stroke derive from therapy. Predictors and biomarkers of treatment effect might therefore be useful to define
therapy plans for individual patients. Many different measures have been found to predict treatment gains, however few studies have examined multiple predictors in parallel. This suggests the need for a multimodal approach that directly compares multiple measures. Such an approach has been found useful for predicting gains from therapy targeting the upper extremity\textsuperscript{6,7}, but has not been examined for the lower extremity, for which the optimal approach to predicting outcomes may be different given fundamental differences in neural organization\textsuperscript{17,18}. Of 19 candidate predictor measures spanning five assessment categories examined, measures of impairment and brain function best predicted change in gait velocity. This study also explored the utility of lower extremity-based fMRI measures as biomarkers of treatment effect and found that behavioral gains may be related to activation volume increases in both hemispheres. These findings might inform design of studies of restorative therapies targeting the lower limb after stroke.

Change in gait velocity across treatment was best predicted by a multimodal model that incorporated baseline measures of cortical function (greater ipsilesional foot sensorimotor cortex fMRI activation volume) and behavior (less lower extremity impairment). Consistent with prior reports\textsuperscript{19-22}, bivariate analyses found that many different types of baseline measures significantly predicted treatment gains (Table 2), including measures of medical history, impairment, disability, and brain function. However, prior studies predicting lower extremity treatment gains did not include an fMRI measure of cortical function. When such a measure was added to the multivariate model, it emerged as an independent and significant predictor, a result concordant with prior studies that measured cortical function using evoked potentials\textsuperscript{23, 24}. The finding that an fMRI measure of cortical function combined with a measure of impairment best predicts treatment gains precisely echoes the findings of one prior therapeutic study that targeted upper extremity\textsuperscript{7}, but not a second study\textsuperscript{6}, the latter possibly reflecting use of different injury measures or testing procedures. The current results support the use of a multimodal approach\textsuperscript{25} for predicting treatment gains, including a measure of cortical function\textsuperscript{6,26}, and extend this approach to therapies that target the lower extremity.

The current study also explored whether changes in fMRI measures over time correlated with change in behavioral measures and therefore have potential utility as biomarkers of treatment effect. The change in activation volume within foot primary sensorimotor cortex of each hemisphere was related to certain behavioral gains, suggesting that these fMRI measures may provide insights into neural-mediated behavioral gains\textsuperscript{27}; for example, change in contralesional activation volume correlated with change in leg FM score ($p=0.0043$). However, while prior reports support current findings (e.g., increased ipsilesional\textsuperscript{28-30} or bilateral\textsuperscript{31} activation paralleling behavioral improvement with gait training), these findings did not survive formal Bonferroni correction (alpha=0.0042). Further studies of cortical function are needed to better understand whether such measures may be useful as biomarkers of lower extremity treatment effects.

Interestingly, sensorimotor cortex activation did not correlate with behavioral status before therapy but did at week-12. Thus, at baseline, no fMRI measure correlated with gait velocity but after therapy, all three behavioral measures correlated significantly with ipsilesional and with contralesional sensorimotor cortex activation volume. Brain activation was not tightly...
linked with behavior at baseline but became so with the motor system plasticity stimulated by nine weeks of therapy. A prior cross-sectional fMRI study of subjects with chronic stroke found contralesional activation during paretic foot movement to have a negative correlation with lower limb function\textsuperscript{32}, in contrast to the positive correlation identified at week-12 in the current study; these divergent results might reflect details of that study\textsuperscript{32} such as stroke topography (subcortical only), greater time post-stroke (37 months), and choice of fMRI metrics.

The current findings provide useful insight into predictors and biomarkers of treatment effect in studies targeting the lower extremity in patients with chronic stroke. Results may be useful for development of entry criteria and stratification measures in clinical trials. Addition of an interim fMRI study acquired after initiating therapy might improve prediction of treatment gains—determining whether treatment is engaging sensorimotor pathways and inducing cortical reorganization could improve prediction\textsuperscript{33}. Measures of injury did not achieve significance in the current study, but this might in part reflect the specific patterns of injury present in the current cohort, as lesion characteristics influence cortical plasticity\textsuperscript{34} and response to treatments targeting the lower extremity\textsuperscript{35}. One weakness of the current study is the absence of neurophysiology measures in the trial protocol. Heterogeneity of enrollee time post-stroke might confound data interpretation, although this issue’s impact may be limited because the earliest a subject was enrolled was 71 days post-stroke (Table 1), and the first dose of study medication was given in the chronic phase (i.e., at least 3-months post-stroke) in all but two subjects. Subjects averaged 212 days post-stroke at enrollment, potentially limiting the direct relevance of current findings to stroke rehabilitation care, most of which is administered in the first month post-stroke. However, many studies\textsuperscript{36}, in addition to the present study, have reported that treatment initiated in the chronic phase after stroke can improve motor status.

In current practice, behavioral assessments are mainly used to distinguish subgroups of stroke patients, e.g., to guide rehabilitation therapy, stratify clinical trial enrollees, or predict treatment gains. Consistent with this approach, the current study found that leg FM score alone was a significant predictor of change in gait velocity ($r=0.46$). However, leg FM score together with ipsilesional fMRI activation volume in a multivariate model predicted change in gait velocity more precisely ($r^2=0.63$, thus $r=0.79$), suggesting that these two baseline measures reflect the capacity to achieve gains in motor control for walking, resulting in higher speed. The current results suggest that a multivariate approach that adds a measure of brain activation to behavioral assessments substantially improves the ability to predict treatment gains.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

**Funding Sources:** This work was supported by a grant from GlaxoSmithKline to Dr. Cramer and by funds from NIH (K24 HD074722, R01 HD46740, and 5M011 RR-00827).

*Stroke.* Author manuscript; available in PMC 2015 August 01.
References


Figure 1.
Study time course. After baseline assessments, subjects received 9-weeks of daily study medication (ropinirole or placebo), with 4-weeks of twice/week physical therapy added on week five. Three weeks after end of therapy, MRI and final exams were performed.
Figure 2.
(A) Activation volume in ipsilesional foot primary sensorimotor cortex at baseline predicts treatment-related gains in gait velocity (r=0.54, p=0.01). Activation volume=8 mm$^3$ voxels, gait velocity=m/sec. (B) The fMRI images (slices at MNI z=+62, +64, and +66) from two representative subjects, both with stroke in right hemisphere. White arrows bracket ipsilesional foot primary sensorimotor cortex.
## Table 1

### Baseline assessments

<table>
<thead>
<tr>
<th>Medical history</th>
<th>Baseline value</th>
<th>Change from baseline to week-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61±14 (32-89)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>23/10</td>
<td></td>
</tr>
<tr>
<td>Time Post-stroke (days)</td>
<td>212±104 (71-437)</td>
<td></td>
</tr>
<tr>
<td>History of Hypertension</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>History of Hyperlipidemia</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>History of Diabetes Mellitus</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

### Impairment

| Gait Velocity (m/sec)                  | 0.52±0.33 (0.03-1.3) | 0.22±0.21 |
| Gait Endurance (number meters over 6 min) | 137±92 (8-284)     | 55±60     |
| Leg FM Score                           | 22±5 (14-34)       | 1.9±3.3   |
| Arm FM Score                           | 29±17 (7-61)       |           |
| FIM Ambulation Score                   | 5.3±1.2 (2-7)      |           |

### Disability

| Modified Rankin Score                  | 0.18±0.46 (0-2)    |                                 |
| Hamilton Depression Score              | 6±4               | -0.4±4.8                          |
| Barthel Index                          | 81±18             | 3.4±8.8                           |
| SIS-16                                 | 57±10             | 5.8±8.2                           |

### Brain injury

| Infarct Volume (cc)                    | 34±61 (0.13-281)  |                                 |
| % Corticospinal Tract Injury           | 49±39 (0-100)     |                                 |

### Brain function

| Activation volume, Ipsilesional Foot Primary Sensorimotor Cortex | 333±347 | 54±239 |
| Activation Volume, Contralesional Foot Primary Sensorimotor Cortex | 212±193 | 46±232 |
| Activation Magnitude, Ipsilesional Foot Primary Sensorimotor Cortex | 0.18±0.32 | 0.07±0.23 |
| Activation Magnitude, Contralesional Foot Primary Sensorimotor Cortex | 0.15±0.29 | 0.12±0.23 |

Measures in bold indicate that change over time was significant (p<0.04 to p<0.0001); change in contralesional activation magnitude showed a trend (p=0.056). Values are mean±SD (range); activation volume=8mm³ voxels; activation magnitude=task-related % signal change.
Table 2
Bivariate predictors of change in gait velocity from baseline to week-12

<table>
<thead>
<tr>
<th>Predictive variable</th>
<th>n</th>
<th>r</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical history</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>33</td>
<td>0.04</td>
<td>0.84</td>
</tr>
<tr>
<td>Time Post-stroke</td>
<td>33</td>
<td>-0.52</td>
<td>0.002</td>
</tr>
<tr>
<td># Outside Physical Therapy Sessions</td>
<td>33</td>
<td>0.12</td>
<td>0.49</td>
</tr>
<tr>
<td># All Outside Therapy Sessions</td>
<td>33</td>
<td>0.34</td>
<td>0.054</td>
</tr>
<tr>
<td><strong>Impairment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gait Velocity</td>
<td>33</td>
<td>0.27</td>
<td>0.13</td>
</tr>
<tr>
<td>Gait Endurance</td>
<td>33</td>
<td>0.46</td>
<td>0.007</td>
</tr>
<tr>
<td>Leg FM score</td>
<td>33</td>
<td>0.46</td>
<td>0.007</td>
</tr>
<tr>
<td>Arm FM score</td>
<td>33</td>
<td>0.43</td>
<td>0.01</td>
</tr>
<tr>
<td>FIM Ambulation Score</td>
<td>33</td>
<td>0.47</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>Disability</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Rankin Score</td>
<td>33</td>
<td>0.05</td>
<td>0.80</td>
</tr>
<tr>
<td>Hamilton Depression Score</td>
<td>33</td>
<td>0.15</td>
<td>0.40</td>
</tr>
<tr>
<td>Barthel Index</td>
<td>33</td>
<td>0.51</td>
<td>0.003</td>
</tr>
<tr>
<td>SIS-16 Score</td>
<td>33</td>
<td>0.36</td>
<td>0.042</td>
</tr>
<tr>
<td><strong>Brain injury</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infarct Volume</td>
<td>24</td>
<td>0.02</td>
<td>0.92</td>
</tr>
<tr>
<td>% Corticospinal Tract Injury</td>
<td>24</td>
<td>-0.06</td>
<td>0.80</td>
</tr>
<tr>
<td><strong>Brain function</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activation Volume, Ipsilesional Foot Primary Sensorimotor Cortex</td>
<td>20</td>
<td>0.54</td>
<td>0.01</td>
</tr>
<tr>
<td>Activation Volume, Contralesional Foot Primary Sensorimotor Cortex</td>
<td>20</td>
<td>0.34</td>
<td>0.15</td>
</tr>
<tr>
<td>Activation Magnitude, Ipsilesional Foot Primary Sensorimotor Cortex</td>
<td>20</td>
<td>0.34</td>
<td>0.15</td>
</tr>
<tr>
<td>Activation Magnitude, Contralesional Foot Primary Sensorimotor Cortex</td>
<td>20</td>
<td>0.34</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Correlation between 19 independent variables measured at baseline and the primary study outcome measure, change in gait velocity. For normally distributed variables, r is the Pearson correlation coefficient; for non-normally distributed, r is Spearman's rho. FM=Fugl-Meyer, FIM=Functional Independence Measure, SIS=Stroke Impact Scale.